SuperworthFossil profit margin FOSL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −7.1%
- Operating margin, 12 months
- −0.6%
- Net margin on a year earlier
- −1.6 pts
- Peer median
- 7.8%
Over the twelve months to Jul 4, 2026, Fossil kept −7.1% of its revenue as net profit, with an operating margin of −0.6% and a gross margin of 56.7%.
Five years earlier its net margin was −0.8%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.8% | −1.9% | 56.1% |
| FY2024 | −9.0% | −9.1% | 52.2% |
| FY2023 | −11.1% | −10.1% | 48.1% |
| FY2022 | −2.6% | −0.1% | 49.4% |
| FY2021 | 1.4% | 5.0% | 51.7% |
| FY2020 | −6.0% | −8.4% | 47.7% |
| FY2019 | −2.4% | −1.3% | 49.6% |
| FY2018 | −0.1% | 2.5% | 52.7% |
| FY2017 | −17.1% | −15.2% | 48.7% |
| FY2016 | 2.6% | 4.2% | 51.9% |
| FY2015 | 6.8% | 9.0% | 54.3% |
| FY2014 | 10.7% | 16.1% | 57.0% |
| FY2013 | 11.6% | 17.2% | 57.1% |
| FY2012 | 12.0% | 17.1% | 56.2% |
| FY2011 | 11.5% | 18.4% | 56.1% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −7.1% | −1.6 pts | −0.6% | |
| Q1 FY26 | −6.2% | +2.4 pts | −0.0% | |
| Q4 FY25 | −7.8% | +1.2 pts | −1.9% | |
| Q3 FY25 | −6.3% | +3.8 pts | −3.4% | |
| Q2 FY25 | −5.5% | +6.4 pts | −3.6% | |
| Q1 FY25 | −8.5% | +1.9 pts | −7.3% | |
| Q4 FY24 | −9.0% | +2.2 pts | −9.1% | |
| Q3 FY24 | −10.1% | −0.8 pts | −9.1% | |
| Q2 FY24 | −11.9% | −7.4 pts | −10.4% | |
| Q1 FY24 | −10.4% | −6.5 pts | −10.1% | |
| Q4 FY23 | −11.1% | −8.5 pts | −10.1% | |
| Q3 FY23 | −9.3% | −8.4 pts | −7.9% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Fossil's size, closest first, today.
| Company | Profit margin |
|---|---|
| FOSLFossil | −7.1% |
| EMBCEmbecta | 8.6% |
| TCMDTactile Systems Technology | 7.1% |
| INFUInfuSystem | 6.0% |
| MDXGMimedx | 1.8% |
| UTMDUtah Medical Products | 29.0% |
| MOVMovado | 6.0% |
| PDEXPro DEX | 17.6% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| BVSBioventus | 9.4% |
| Peer median | 7.8% |
Where Fossil ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Fossil
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.